{"title":"抓住希望：将耐药癫痫的细胞治疗推向临床。","authors":"Ana Beltrán Arranz, Benedikt Berninger","doi":"10.1016/j.stem.2023.08.006","DOIUrl":null,"url":null,"abstract":"<p><p>In this issue of Cell Stem Cell, Bershteyn et al.<sup>1</sup> developed a human interneuron cell therapy that reduced spontaneous seizure activity in a mouse model of mesial temporal lobe epilepsy (MTLE). The data presented here support an ongoing phase 1/2 clinical trial for the treatment of pharmaco-resistant epilepsy in patients.</p>","PeriodicalId":93928,"journal":{"name":"Cell stem cell","volume":"30 10","pages":"1287-1289"},"PeriodicalIF":0.0000,"publicationDate":"2023-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Seizing hope: Advancing cell therapy for pharmaco-resistant epilepsy toward the clinic.\",\"authors\":\"Ana Beltrán Arranz, Benedikt Berninger\",\"doi\":\"10.1016/j.stem.2023.08.006\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>In this issue of Cell Stem Cell, Bershteyn et al.<sup>1</sup> developed a human interneuron cell therapy that reduced spontaneous seizure activity in a mouse model of mesial temporal lobe epilepsy (MTLE). The data presented here support an ongoing phase 1/2 clinical trial for the treatment of pharmaco-resistant epilepsy in patients.</p>\",\"PeriodicalId\":93928,\"journal\":{\"name\":\"Cell stem cell\",\"volume\":\"30 10\",\"pages\":\"1287-1289\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-10-05\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cell stem cell\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1016/j.stem.2023.08.006\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cell stem cell","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.stem.2023.08.006","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Seizing hope: Advancing cell therapy for pharmaco-resistant epilepsy toward the clinic.
In this issue of Cell Stem Cell, Bershteyn et al.1 developed a human interneuron cell therapy that reduced spontaneous seizure activity in a mouse model of mesial temporal lobe epilepsy (MTLE). The data presented here support an ongoing phase 1/2 clinical trial for the treatment of pharmaco-resistant epilepsy in patients.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
